TransCode Therapeutics Bolsa (NASDAQ: RNAZ)

Últimas noticias sobre TransCode Therapeutics (NASDAQ:RNAZ) Bolsa

TransCode Therapeutics

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

Editor&#8217;s Note: The article has been updated with comments from Mercedes-Benz and Toyota.
The National Highway Traffic Safety Administration (NHTSA) has issued recalls for vehicles from Mercedes-Benz USA LLC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>), (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGYY#OTC">MBGYY</a>), Toyota Motors Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), and Mazda (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MZDAF#OTC">MZDAF</a>) due to software-related issues, according to the safety recall reports.
On Friday, according to an NHTSA recall report, Mercedes-Benz USA is recalling 27,190 vehicles, including the 2021-2023 Mercedes-Benz Maybach S580 and S580 models. The recall is due to a defect in the Engine Control Unit software, which may lead to increased exhaust temperatures and potential damage to surrounding components, increasing the risk of fire.
See Also: <a href="https://www.benzinga.com/news/24/09/41019716/trump-pledges-100-tariffs-on-all-cars-made-in-mexico-the-only-way-theyll-get-rid-of-that-tariff-is?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Pledges 100% Tariffs On All Cars Made In Mexico: &#8216;The Only Way They&#8217;ll Get Rid Of That Tariff Is…&#8217;</a>
Another recall report indicated that Toyota Motors is recalling 42,199 units of the 2023-2024 Toyota Corolla Cross Hybrid. The defect involves the brake actuator&#8217;s skid control ECU software, which may cause a hard brake pedal and reduced braking force during cornering, potentially increasing the risk of a crash.
Additionally, Mazda is also recalling 77,670 units of the 2016-2023 Mazda MX-5 Miata. The issue stems from the SAS control module software, which may cause a higher force airbag deployment during minor crashes, increasing the risk of injury if seat belts are not used.
The recalls are set to begin with dealer notifications in September 2024 and owner notifications by November 2024. Affected owners are advised to contact their respective dealers for a free software update to rectify the issues.
Mercedes-Benz AG confirmed on the issues while Toyota shared their official statement that revealed that Toyota dealers will update the programming of the skid control ECU software for the brake actuator, free of charge while owners of the vehicles will be informed by November.
Mazda has yet to respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> queries.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40981404/us-proposes-ban-on-vehicles-equipped-with-chinese-software-as-team-biden-cracks-down-on-foreign-adve?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">US Proposes Ban On Vehicles Equipped With Chinese Software As Team Biden Cracks Down On &#8216;Foreign Adversaries&#8217; Threatening &#8216;Privacy And Safety Of Americans On The Road&#8217;</a></li>
</ul>
Photo by pisaphotography on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

News

Tech

General

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

MZDAF

Mercedes-Benz, Toyota, Mazda Issue Massive Recalls Over Software Defects: NHTSA Warns Of Fire, Brake And Airbag Risks (UPDATED)

Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled "Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial," is now available on <a href="https://www.globenewswire.com/Tracker?data=Nl6UXJqK5PxdYnsQ2k9McbYZocbRMS4MKLV2cpVlyFXF_54HapWm6mU0FAirsidVyRJoGdVgn-ygFecrv2XkyW4IQ2UAxBFkhUvB8yxhDfq4LegZFQM7vawdfG2BnWnL2XAXhsACHTItYeG3E_ACXU9biZRgZErPrZ2j2_RgH6I=">The Lancet Oncology</a> website and in the <a href="https://www.globenewswire.com/Tracker?data=HJNadw4C8mOMqoWsq4tfzmcQTwO5_gbc4t2-VyKQqLKxtgnh1b1aAJH-RXwwJ6v7v7SIcea_UQktOXE2ZNObjzo7OR4LOrzU6gfw5ozj4lFHfVDgCaD0vVJvfGpWBhoLJpLYPVea0I_G6NO9-9uOMXuX-M7OHdNnJ5N97f7eztM=">Scientific Manuscripts</a> section on Kura's website. &nbsp;
"The results from the KOMET-001 Phase 1 study are encouraging as they demonstrate meaningful benefit of ziftomenib in NPM1-mutant acute myeloid leukemia (AML), and publication of these data expands the growing evidence supporting the efficacy and safety of ziftomenib in a disease indication of unmet need," said Ghayas C. Issa, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. "We are thankful for the patients and their families for their participation in the KOMET-001 trial and for the scientific community who have contributed to this research to advance more tolerable and effective treatment options for AML patients."
The KOMET-001 study is a Phase 1/2 global, open-label, multi-cohort clinical trial evaluating the safety, tolerability and clinical activity of ziftomenib in relapsed/refractory (R/R) AML. In the Phase 1a dose escalation portion, patients received ziftomenib once daily in 28-day cycles and in the Phase 1b dose validation/expansion portion, patients were randomized to two parallel cohorts at 200 mg and 600 mg. As of the data cutoff on August 30, 2023, 83 patients received one or more doses of ziftomenib and the primary objective of this study was to determine the recommended phase 2 dose (RP2D) based on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity. The results demonstrated promising clinical activity with manageable toxicity in heavily pretreated patients including marrow blast reduction, neutrophil and platelet recovery, transfusion independence, and clearance of measurable residual disease.

KURA

Reported Earlier, Kura's KOMET-001 Study in AML Patients Highlights Efficacy of Ziftomenib, Now Published in The Lancet

Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has been awarded a contract valued up to $1.3 billion to continue work on the F135 Engine Core Upgrade (ECU), which will deliver enhanced durability to the engine. The ECU also provides power and cooling for Block 4 and beyond capabilities for all three variants of the F-35 global enterprise.

Reported Earlier, Pratt & Whitney Secures $1.3B Contract for F-35 Engine Upgrade

OBSIDIAN ENERGY LTD. (TSX:&nbsp;OBE) (NYSE:<a href="https://www.benzinga.com/stock/OBE#NYSE">OBE</a>) ("Obsidian Energy", the "Company", "we", "us" or "our") is pleased to provide an update to our 2024 guidance that includes ongoing strong second half 2024 drilling results that continue to exceed our initial expectations. As a result, we have further increased our 2024 production guidance range to 37,000 to 37,400 boe/d (midpoint of 37,200 boe/d) with associated adjustments to our funds flow from operations ("FFO") and free cash flow ("FCF").
Considering the recent softness in commodity prices and market uncertainty due to global factors, Obsidian Energy has also revised our 2024 capital expenditures downwards by approximately $15 million, reallocating a portion of light oil spending towards incremental share buybacks through our normal course issuer bid ("NCIB") and further debt reduction. In total, the reallocation of capital is only expected to impact average 2024 production by approximately 40 boe/d.
"The continued outperformance of our development program has led to a further increase to our 2024 production guidance," said Stephen Loukas, Obsidian Energy's President and CEO. "However, the recent volatility in both the broader oil and gas markets as well as with our share price has resulted in a dynamic whereby our equity valuation is significantly below new development economics within our light oil portfolio. Accordingly, Obsidian Energy's Board of Directors has approved the postponement of our fourth quarter light oil program (excluding the drilling of our initial delineation well targeting the Belly River formation in our Willesden Green area) and capital reallocation into a combination of incremental share buybacks and additional debt repayment. Notwithstanding a minor impact to 2024 production, we believe that this decision will result in superior FFO and FCF per share metrics. Moreover, it will afford Obsidian Energy's shareholders greater exposure to our growing Peace River play, preserving light oil inventory for more favourable market while still meeting our 50,000 boe/d 2026 production target."
REVISED 2024 GUIDANCE
We have revised our 2024 guidance with annual production expected to be between 37,000 to 37,400 boe/d with a midpoint of 37,200 boe/d - a 15 percent increase from 32,275 boe/d in 2023 - and an approximate $15 million decrease to capital expenditures that will be reallocated to further share buybacks and debt reduction. Although we have lowered our WTI forecast to US$72.50/bbl for the remainder of 2024, our FFO increased by $5 million to $420 million, resulting in a 2024 net debt to FFO of approximately 0.9 times and a related increase to FCF by approximately $17 million to $69 million. Our revised 2024 guidance, incorporating key assumptions used by the Company, is as follows:

Guidance

Reported Earlier, Obsidian Energy Increases 2024 Production Guidance by 15%, Cuts Capital Spending by $15M, Adjusts Capital for Share Buybacks

Vice Presidential candidates from either side of the aisle, Sen. J.D. Vance (R-Ohio) and Minnesota Governor Tim Walz will <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41107455/walz-vs-vance-vp-debate-betting-odds-what-candidate-is-favored-plus-how-to-watch-likely-to">take on each other in a debate to be televised live on CBS News on Tuesday, </a>and former President Donald Trump&#8216;s niece Mary Trump weighed in on the event in her substack post.
Media Apathy: CBS, owned by Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>), said it would not fact-check the debate in real-time but would do it in its live blog and on socials as well as in its post-debate coverage, said Mary Trump in the post published on Monday. The presidential debate between Donald Trump and Vice President Kamala Harris, hosted by ABC News, had real-time fact-checking.
The statement from CBS that moderators Margaret Brennan and Norah O'Donnell &#8220;will facilitate&#8221; opportunities for Vance and Walz to confront each other sounded like &#8220;on one hand CBS wants a food fight and, on the other, as if its comfortable giving a huge advantage to the one debate participant—Vance—who is known, like his running mate, for being an inveterate liar,&#8221; Mary Trump said.
The psychologist also said if the media doesn&#8217;t take up the onus of fact-checking information, it is incumbent on the public to spot a lie when they hear or read one.
See Also: <a href="https://www.benzinga.com/news/24/08/40278004/vance-vs-walz-how-do-trump-and-kamala-harris-vice-president-picks-net-worth-compare">Vance Vs. Walz: Comparing Net Worth Of Trump And Kamala Harris&#8217; VP Picks</a>
Violence In The Cards: If Donald Trump is elected again, there will be blood, given he has long been targeting vulnerable communities and setting them up if he loses the election,<a href="https://www.marytrump.org/p/irony-diesagain"> said</a> Mary Trump in a separate post. &#8220;The more desperate he becomes, the more openly Donald fantasizes about violence being unleashed on his behalf,&#8221; she said.
Mary Trump noted that last weekend in Pennsylvania Donald Trump lied about shoplifting and proposed &#8220;one real rough nasty day&#8221; to let police do whatever they want to alleged perpetrators.&nbsp;
&#8220;This isn't fiction and what Donald is calling for has an historical precedent,&#8221; she added. 
&#8220;Donald is clearly signaling to his extremist followers that he will not only condone but will actively welcome such episodes of violence and intimidation here,&#8221; Mary Trump said. He has stated clearly on several occasions that he wants to use law enforcement and the U.S. military against American citizens, she said. 
While noting that Donald Trump has repeatedly said America&#8217;s enemies are those within and not China, Russia or North Korea, Mary Trump said her uncle believes deeply that anyone who opposes him or stands up to him is his enemy and, because he is an authoritarian, by extension, the enemy of the United States. 
&#8220;My uncle sees violence committed on his behalf as the ultimate sign of love and loyalty. He wants Americans to bleed—for him,&#8221; she added. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock

Politics

Media

PARA

Trump's Niece Says Vance Handed Down Huge 'Advantage' In Debate With Walz, Labels Him 'Inveterate Liar'

Earnings

Reported Earlier, SunLink Health Systems Q4 EPS $0.61 Up From $(0.20) YoY, Sales $7.91M Down From $8.01M YoY

Older Model S and Model X vehicles from EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will receive the <a href="https://www.benzinga.com/news/24/09/40681024/tesla-owners-can-now-summon-their-vehicles-using-their-phones">actually smart summon feature</a> that allows drivers to summon their vehicles in parking lots in the last quarter of 2024, company executive Ashok Elluswamy said on Monday.
What Happened: &#8220;Actually Smart Summon will come to legacy S/X in Q4,&#8221; Elluswamy wrote on social media platform X. 
Elluswamy, who is the Director of Autopilot software at Tesla, was responding to a user who flagged that though the company started rolling out the feature to newer model years of the vehicles in early September, older vehicle owners are still waiting. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actually Smart Summon will come to legacy S/X in Q4.
&mdash; Ashok Elluswamy (@aelluswamy) <a href="https://twitter.com/aelluswamy/status/1840833897699172599?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Actually Smart Summon is the latest iteration of the smart summon feature which was removed in 2022 with the company's removal of ultrasonic sensors to rely on cameras to provide driver assistance features.
Actually Smart Summon will allow users to summon their Tesla cars to a nearby particular location and banish them once they are done using it with the Tesla app.
Tesla in September also deployed parking assistance features and its full self-driving (FSD) driver assistance software on the <a href="https://www.benzinga.com/news/24/09/41086839/tesla-cybertruck-starts-receiving-highly-anticipated-fsd-software">Cybertruck- its latest EV offering</a>. FSD, contrary to its name, does not enable autonomous driving but requires active driver supervision. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41088324/spacexs-falcon-9-rocket-grounded-3rd-time-in-3-months-launch-put-on-hold-as-company-hunts-for-root-c">SpaceX&#8217;s Falcon 9 Rocket Grounded 3rd Time In 3 Months: Launch Put On Hold As Company Hunts For &#8216;Root Cause&#8217;</a></li>
</ul>
Photo courtesy: Unsplash

TSLA

Tesla Senior Exec Says Drivers Of Older Model S, X Vehicles Can Summon Them By Last Quarter Of 2024

Equity LifeStyle Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) (referred to herein as the "Company," "we," "us," and "our") reported today its preliminary assessment of the impact of Hurricane Helene on its Florida, North Carolina and South Carolina properties.
No injuries to our residents, guests or employees have been reported. Certain properties were affected by flooding, wind, wind-blown debris, and falling trees and branches. We are in the process of estimating costs associated with cleanup and restoration efforts. We believe that we have adequate insurance, subject to deductibles, including business interruption coverage. At this time, we do not believe that Hurricane Helene will significantly impact our results of operations or our financial condition on a consolidated basis

Reported Earlier, Equity LifeStyle Properties Reports Minimal Impact from Hurricane Helene, Cleanup Underway

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax&#xAE;.
Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on the financial terms of the deal are being disclosed.

Government

Regulations

MRNA

Reported Earlier, Moderna and Cenra Healthcare Join Forces to Promote COVID-19 and Respiratory Vaccines in Taiwan

Over the years, billionaire investor Mark Cuban and former President Donald Trump have shared a multifaceted relationship. Their complicated and rather chaotic history started as being TV rivals.
What Happened: In 2004, Cuban&#8217;s &#8220;The Benefactor&#8221; and Trump&#8217;s &#8220;The Apprentice&#8221; began airing. While The Apprentice ran for 15 seasons, Cuban&#8217;s The Benefactor was canceled after just six episodes.
At the time, in a blog post titled &#8220;Thank you, Donald,&#8221; Cuban expressed his frustration after Trump told the Chicago Sun-Times, &#8220;You&#8217;ll have 100 people trying to do shows a little bit like us.&#8221;
&#8220;Let's get some things cleared up in case anyone is confused. The Benefactor is going to be nothing like The Apprentice. Why? Because, Donald, we are not alike in any way,&#8221; the &#8220;Shark Tank&#8221; star stated.
In the same blog post, Cuban reminisced about meeting Trump at a 1999 Super Bowl party at Mar-a-Lago, after which Trump invited him to meet in New York.
According to the billionaire, the former President&#8217;s office walls were completely covered with photos and magazine covers featuring him.
See Also: <a href="https://www.benzinga.com/general/politics/24/09/41079936/shaq-called-trump-a-straight-up-guy-before-presidency-i-think-he-just-says-it-wrong-but-did-the-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shaq Called Trump &#8216;A Straight-Up Guy&#8217; Before Presidency, &#8216;I Think He Just Says It Wrong&#8217;</a>
&#8220;After leaving your office, I promised myself that if I ever got liquid and had an obscene amount of money in the bank, I would make a point not to remind myself and everyone else around me of it every minute of every day unlike you,&#8221; he said, adding, &#8220;I guess our definition of success is just completely different.&#8221;
Following Cuban&#8217;s blog post, Trump stated he didn&#8217;t recall meeting him. In response, Cuban wrote a follow-up post titled &#8220;Of course you don&#8217;t remember, Donald.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A history of Donald Trump and Mark Cuban&#39;s &#39;love-hate relationship&#39; <a href="https://t.co/wDeYT6En1y">https://t.co/wDeYT6En1y</a> via <a href="https://twitter.com/BusinessInsider?ref_src=twsrc%5Etfw">@businessinsider</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1840871506835902749?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Five years later, in 2009, Cuban praised Trump for his marketing nous. &#8220;Donald&#8217;s amazing. He sets the standard for marketing and promotion and to get him involved in MMA and to partner with him is an amazing opportunity for HDNet,&#8221; he said.
Why It Matters: Despite their rivalry, Cuban initially supported Trump&#8217;s political aspirations but later became a vocal critic due to their differing views on success and the Republican nominee&#8217;s incessant self-promotion.
The duo also collaborated in 2009 to promote a mixed martial arts (MMA) event through Cuban&#8217;s HDNet network.
In 2017, Trump also retaliated against Cuban, saying the billionaire wasn&#8217;t smart enough to run for president.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I know Mark Cuban well. He backed me big-time but I wasn&#39;t interested in taking all of his calls.He&#39;s not smart enough to run for president!
&mdash; Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/830769247185952772?ref_src=twsrc%5Etfw">February 12, 2017</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, Cuban <a href="https://www.benzinga.com/news/24/09/41078897/billionaire-mark-cuban-admits-to-being-a-trump-supporter-in-2016-credits-long-conversation-with-form">admitted to supporting</a> Trump in 2016 but said that a conversation with his running mate JD Vance led to a change of heart.
Earlier this month, the <a href="https://www.benzinga.com/news/24/09/40849505/mark-cuban-says-he-truly-does-not-hate-trump-but-calls-him-a-lousy-president-if-he-wasnt-running">billionaire also said</a>, &#8220;I truly don't hate him [Trump] at all. I just think he was&nbsp;and would be a lousy&nbsp;president.&#8221;
In August while speaking with Vivek Ramaswamy, Cuban said, &#8220;I actually started off supporting Donald and then I got to know him better. I was like, ‘He's great, he's not a typical Stepford candidate.' I thought that was a positive, and then I got to know him.&#8221;
He added, &#8220;He was unethical then, and he&#8217;s still unethical.&#8221;
Cuban has been <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41032465/mark-cuban-is-one-of-kamala-harris-most-effective-surrogates-says-former-sc-house-rep-baka">openly supporting</a> Vice President Kamala Harris, the Democratic candidate for the 2024 presidential election.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41083520/larry-hogan-says-trump-questioning-kamala-harris-intelligence-outrageous-and-unacceptable-he-is-his?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Larry Hogan Says Trump Questioning Kamala Harris&#8217; Intelligence &#8216;Outrageous And Unacceptable&#8217;: He Is His Own &#8216;Worst Enemy&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Mark Cuban Once Supported Trump's Political Aspirations And Called Him 'Amazing,' But The Former TV Rivals Have Shared A Love-Hate Relationship: The 'Shark Tank' Star Made This Promise To Himself After Leaving Ex-President's Office In 2004

Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>, HKEX: 2015)))), a leader in China's new energy vehicle market, today announced that it delivered&nbsp;53,709 vehicles in September 2024, up 48.9% year over year. This brought the Company's third-quarter deliveries to 152,831, increasing by 45.4% year over year. As of September 30, 2024, Li Auto had delivered a total of&nbsp;341,812 vehicles in 2024, with cumulative deliveries reaching 975,176. &nbsp;

Reported Earlier, Li Auto Delivered 53,709 Vehicles In September, Up By 48.9% YoY

ZEEKR Intelligent Technology Holding Limited ("ZEEKR" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>), a global premium electric mobility technology company, today announced its delivery results for September 2024.
ZEEKR delivered 21,333 vehicles in September 2024, a 77% year-over-year increase. Year-to-date,&nbsp;ZEEKR has delivered 142,873 vehicles in 2024, representing 81% growth over the same period last year. As of the end of September 2024,&nbsp;ZEEKR's cumulative deliveries reached 339,506.
On September 20, 2024, ZEEKR&nbsp;officially&nbsp;unveiled its premium electric five-seater SUV, the ZEEKR 7X, with deliveries commencing the very next day. The ZEEKR 7X is designed to challenge the conventional, seamlessly combining luxurious comfort with robust off-road capabilities, making it ideal for both urban and challenging conditions.&nbsp;

Reported Earlier, Zeekr Delivered 21,333 Vehicles In September, Up By 77% YoY

Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GFR#TSX">GFR</a>) ("Greenfire" or the "Company"), a Calgary-based energy company focused on the production and development of thermal energy resources from the Athabasca region of Alberta, Canada announces that the Alberta Securities Commission ("ASC") has set November 5, 2024 as the date for the hearing in respect of the application made by certain limited partnerships managed by Waterous Energy Fund Management Corp. (collectively, "WEF") and parties that it has entered into share purchase agreements with, namely Allard Services Limited ("Allard"), a corporation controlled by former director and Greenfire Board Chair Julian McIntyre, and Annapurna Limited ("Annapurna"), a corporation controlled by former Greenfire director Venkat Siva, and Modro Holdings LLC (together with Allard and Annapurna, the "Selling Shareholders") requesting that the ASC, among other things, cease trade the Company's shareholder protection rights plan agreement (the "Rights Plan").
Greenfire adopted the Rights Plan following the announcement on September 16, 2024 that WEF had entered into agreements with each of the Selling Shareholders to acquire 43.3% of the issued and outstanding common shares of the Company. The Company intends to defend the necessity of its Rights Plan at the ASC hearing to ensure, to the extent possible, that all shareholders of Greenfire are treated fairly and equally in connection with any unsolicited take-over bid or other attempt to acquire control of Greenfire, and to provide the Board sufficient opportunity to identify, develop and negotiate potential value-enhancing alternatives, if available, that would benefit all shareholders of the Company.
Greenfire also announces that today each of Julian McIntyre, the principal of Selling Shareholder Allard, and Venkat Siva, the principal of Selling Shareholder Annapurna, has tendered their resignation as a director of the Company.

TSX:GFR

Reported Earlier, Greenfire Faces Key Alberta Securities Commission Hearing Over Shareholder Rights Plan Amid Takeover Bid, Former Directors Resign

NASDAQ-listed <a href="https://pr.report/35db">AGAPE ATP Corporation ("ATPC")</a>, is proud to announce a strategic collaboration with <a href="https://pr.report/35dc">FORMEDIC Technologies Sdn. Bhd. ("FORMEDIC Technologies")</a> to introduce <a href="https://pr.report/35dd">LEGA</a>, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.
LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases ("COPD"), pneumonia, bronchiectasis, and other lung-related conditions by providing critical support for airway clearance and secretion management. LEGA helps to manage secretion drainage and airway clearance, offering much-needed relief to patients both adults and children, facing respiratory difficulties in both hospital and home care settings. This device has already gained significant traction in the medical field, with close to 2,000 units used in major hospitals and rehabilitation centres in Malaysia and globally.
For ATPC, this collaboration brings opportunities in the <a href="https://pr.report/35de">fast-growing respiratory care market, estimated to reach USD 25.95 billion in 2024, with a strong growth trajectory, estimating it to hit USD 49.84 billion by 2031</a>1. As respiratory diseases continue to rise globally, this partnership positions ATPC to capitalise on the increasing demand for advanced respiratory solutions, as well as diversifying its wellness portfolio with a proven medical device.

ATPC

Reported Earlier, AGAPE ATP and FORMEDIC Partner to Launch Advanced Respiratory Device LEGA for COPD and Lung Care

Shigeru Ishiba has been elected as Japan&#8217;s new prime minister, replacing Fumio Kishida and raising questions about future U.S.-Japan relations. 
What Happened: Experts predict how Shigeru&#8217;s appointment might crop up changes in the relations between Tokyo and Washington, as <a href="https://www.politico.com/news/magazine/2024/09/29/japans-prime-minister-ishiba-00181546">reported </a>by Politico on Monday. According to Jesper Koll, a German-born economist in Tokyo, Ishiba must overcome his reputation for micromanagement and stubbornness. Ishiba lacks a grand vision, Koll added.
For Washington, Ishiba&#8217;s stance on military relations is crucial. He has suggested revising the U.S. forces deployment agreement and amending Japan&#8217;s pacifist constitution. Ishiba also proposed an Asian NATO, potentially elevating Japan to a peer ally of the U.S.
Gerry Curtis, a retired Columbia scholar, noted that Ishiba views the current U.S. deal as outdated.
"He could be a problem for the U.S.," he said.
Ken Weinstein, a prominent Japan watcher, described Ishiba as the "hardest for Americans to read&#8221; among the other candidates.
A Japanese official explained that 60% of Ishiba&#8217;s motivation is to enhance deterrence and strengthen the alliance, while 40% is about restoring Japanese sovereignty. This dual motive makes Washington uneasy.
Ishiba stated that security issues would be discussed with the next U.S. president post-November elections. Additionally, Japan faces challenges from U.S. protectionist trade policies and restrictions on technology transfers to China, impacting Japanese manufacturers.
Hiro Akita of Nikkei described Ishiba as a realist who understands Japan must adapt to a changing world. While not seeking to push America back, Ishiba&#8217;s leadership could still stir the waters of U.S.-Japan relations.
See Also: <a href="https://www.benzinga.com/general/politics/24/09/41079936/shaq-called-trump-a-straight-up-guy-before-presidency-i-think-he-just-says-it-wrong-but-did-the-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shaq Called Trump &#8216;A Straight-Up Guy&#8217; Before Presidency, &#8216;I Think He Just Says It Wrong&#8217; – But Did The NBA Legend Actually Vote For Trump In 2016?</a>
Despite his reputation for micromanagement, Ishiba&#8217;s election marks a shift from the policies of former Prime Minister Shinzo Abe. His pragmatic stance could bring changes to Japan&#8217;s domestic and international policies.
Why It Matters: The election of Shigeru Ishiba has already had significant economic repercussions. On Monday, Japan&#8217;s key stock market gauge<a href="https://www.benzinga.com/markets/asia/24/09/41084907/japans-nikkei-plummets-over-2-000-points-amid-change-of-guard-while-chinese-market-extends-stimulus">, the Nikkei 225</a>, plummeted over 2,000 points, or 5.02%, amid the change of leadership. The index, heavily reliant on exports, reacted negatively to Ishiba&#8217;s victory, reflecting investor uncertainty about his policies. 
Additionally, Ishiba&#8217;s stance on international trade and defense could <a href="https://www.benzinga.com/news/24/09/40745941/japan-pm-candidate-warns-bidens-opposition-to-nippons-us-steel-acquisition-could-undermine-the-trust">strain Japan&#8217;s relationship</a> with the United States. Earlier this month, Ishiba warned that President Joe Biden&#8216;s opposition to Nippon Steel&#8216;s acquisition of U.S. Steel might undermine trust between the allies. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image by Sakaori via Wikimedia Commons
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Global

Japan's Shigeru Ishiba 'Could Be A Problem' For US, Experts Warn: 'Hardest For Americans To Read'

CPI Card Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) ("CPI" or the "Company"), a payments technology company and leading provider of credit, debit and prepaid card and digital solutions, including Software-as-a-Service (SaaS) based instant issuance, today announced the pricing of a registered underwritten secondary public offering of 1,200,000 shares of the Company's common stock to be sold by certain stockholders affiliated with Parallel49 Equity (the "selling stockholders"), at a public offering price of $21.00 per share. The underwriters were also granted a 30-day option to purchase up to an additional 180,000 shares of common stock from the selling stockholders at the public offering price, less the underwriting discount. The offering is expected to close on or about October 2, 2024, subject to the satisfaction of customary closing conditions.
The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of common stock by the selling stockholders. Total gross proceeds from the offering to the selling stockholders, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $25.2 million.

Offerings

PMTS

CPI Card Group Selling Stockholders Priced $25.2M Secondary Public Offering of 1.2M Shares At $21/Share

WISeKey International Holding Ltd. ("WISeKey") ((SIX: WIHN, NASDAQ:<a href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>), a leader in cybersecurity, AI, Blockchain, and IoT operating as a holding company, today announced that will be initiating a awareness campaign to promote a major semiconductor fabrication facility (fab) project in Switzerland which marks a crucial step in the country's journey toward self-reliance in chip production and positions Switzerland as an emerging hub in the semiconductor industry.
For many years, WISeKey has been at the forefront of such efforts and has built an extensive expertise in semiconductors. Via its subsidiary. SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>), which focuses on semiconductors, PKI, and post-quantum technology products, WISeKey offers countries the opportunity to develop their own semiconductor personalization centers through Public-Private Partnerships (PPPs). This initiative aims to reduce reliance on foreign semiconductor manufacturing, thereby enhancing global supply chain security.
The development of a ab in Switzerland will require a careful balance of incentives, support, R&amp;D, innovation, and access to capital. As highly advanced facilities, semiconductor fabs face escalating costs due to various factors, and each project presents unique requirements and cost considerations. WISeKey aims to raise awareness of the essential role a Swiss-based fab will play in building the foundations for the country's innovation landscape. Given the project's complexity and cost, establishing a close partnership and a solid investment case is crucial to its success.
The project's objective in Switzerland is to start with a mini fab (a smaller-scale semiconductor fabrication facility) and gradually expand it into a full-scale semiconductor fab over the next 10 years. This phased approach allows for manageable investment, initial production capabilities, and flexibility to scale operations in line with technological advancements and market demands. Starting with a mini fab can cost between $100 million to $1.5 billion, depending on the desired technology node and production capacity. Over time, the facility can be expanded with the latest equipment and processes, eventually reaching the scale and capability of a full fab, which may involve a total investment of several billion. This gradual growth strategy aligns with Switzerland's goal of fostering a domestic semiconductor ecosystem and innovation cluster.
Currently, Switzerland heavily relies on imports to meet its semiconductor needs. This new fab project is set to mitigate that dependence, enhance the domestic chip production ecosystem, create new jobs, and attract further investments in the technology and space sector. Locally produced chips will become essential for various industries within Switzerland, contributing to a more resilient global supply chain.

LAES

WKEY

WISeKey and SEALSQ Push for Switzerland's First Semiconductor Fab to Boost Domestic Chip Production

XPeng Inc. (("XPENG" or the "Company, NYSE:<a href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), a leading Chinese smart electric vehicle ("Smart EV") company, today announced its vehicle delivery results for September and the third quarter 2024.
In September 2024, XPENG delivered 21,352 Smart EVs, a new record for monthly deliveries, representing increases of 39% year-over-year and 52% over the prior month. At the same time, the first month of deliveries of XPENG MONA M03 exceeded 10,000 units. For the first nine months of 2024, XPENG delivered 98,561 Smart EVs, a 21% increase from the same period last year.
With a broad array of superior configurations and competitive pricing, XPENG MONA M03 has experienced a significant increase in orders since its market launch. XPENG and supply chain partners are sparing no effort to prepare for XPENG MONA M03's further production ramp-up.
In September, XNGP's monthly active user penetration rate in urban driving reached 83%. XPENG rolled out its AI Tianji XOS 5.3 to all eligible owners in China on September 25, enhancing their experience with 32 feature updates and 38 functional upgrades. Empowered by end-to-end large AI models, XPENG's ADAS features can deliver seamless smart driving on all public roads, including passing electronic toll collection (ETC), navigating U-turns and roundabouts, and much more.
Additionally, after successful launch events in Madrid and Lisbon in September, XPENG officially introduced the G9, G6 and P7 models to the Spanish and Portuguese markets.
Looking ahead, the Company expects to unveil XPENG P7+, positioned as AI-defined car, in October 2024. XPENG will also showcase its state-of-the-art AI technologies and applications and its new model lineup at the 2024 Paris Motor Show from October 14 to 21.

XPEV

XPeng Reported Delivery Of 21,352 Smart EVs In September 2024, Up By 39% YoY And 52% MoM

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4267071-1&amp;h=2471754948&amp;u=http%3A%2F%2Fwww.group1corp.com%2F&amp;a=Group+1+Automotive%2C+Inc">Group 1 Automotive, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) ("Group 1" or the "Company"), a Fortune 250 automotive retailer with 260 dealerships located in the U.S. and U.K.,&nbsp;announced the appointment of Mark Raban as Chief Executive Officer ("CEO") of Group 1 Automotive U.K.
Raban brings more than 20 years of executive experience in automotive retail operations and finance to Group 1.&nbsp; In this new role, he will oversee the integration of the recently acquired Inchcape dealerships to drive strategic growth in the U.K.&nbsp; Leveraging the Company's expanded brand portfolio and presence, Raban will also focus on enhancing customer experience and reinforcing Group 1's strong OEM partnerships.
"Mark is a proven leader with a history of success in the U.K. motor trade," said Daryl Kenningham, Group 1's President and CEO.&nbsp; "Following the transformative growth of our U.K. business, he will be instrumental in creating a high-performing culture among our team members and engaging customers across our expanded dealership network."
Prior to joining Group 1, Raban progressed from Chief Financial Officer ("CFO") to CEO at Lookers Motor Group, a dealership group in the U.K. and Ireland.&nbsp; Prior to joining Lookers, he served as CFO of Marshall Motor Holdings and held senior finance roles at companies such as Inchcape Retail, Selfridges, and Borders.

Management

Group 1 Automotive Tapped Mark Raban Of Lookers Motor Group as CEO of UK Operations

Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental Biologics License Application (sBLA) for ENHERTU&#xAE; (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting.
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
The U.S. Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is February 1, 2025. The Priority Review follows receipt of Breakthrough Therapy Designation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202408%2F20240819_E1.pdf&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=granted&amp;index=1&amp;md5=c82129aaf52e5fdfcdcfd5c5d0f72567">granted</a> by the FDA for ENHERTU based on data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04494425&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=DESTINY-Breast06&amp;index=2&amp;md5=ecfc5698cd40f1242f214ba893845e59">DESTINY-Breast06</a> phase 3 trial in August 2024.
Hormone receptor (HR) positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still carry some level of HER2 expression.2 It is estimated that up to 85% to 90% of tumors historically classified as HR positive, HER2 negative, may be HER2 low or HER2 ultralow.3,4
The sBLA is based on data from DESTINY-Breast06 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202406%2F20240602_E2.pdf&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=presented&amp;index=3&amp;md5=60d743b75d92125e38563f950191d661">presented</a> as a late-breaking oral session at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and recently published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nejm.org&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=4&amp;md5=1e3a45484df713407df2ad6cdbca0eba">The New England Journal of Medicine</a>. In the overall trial population, ENHERTU reduced the risk of disease progression or death by 37% by blinded independent central review (BICR) versus chemotherapy (hazard ratio [HR] 0.63; 95% confidence interval [CI]: 0.53-0.75; p&lt;0.0001). Median progression-free survival (PFS) was 13.2 months with ENHERTU compared to 8.1 months with chemotherapy.
Results were consistent in patients with HER2 low expression and HER2 ultralow expression. In the primary endpoint analysis of patients with HR positive, HER2 low metastatic breast cancer, median PFS was 13.2 months in the ENHERTU arm compared to 8.1 months in the chemotherapy arm (HR 0.62; 95% CI: 0.51-0.74; p&lt;0.0001), as assessed by BICR. In a prespecified exploratory analysis of patients with HER2 ultralow expression, ENHERTU showed a median PFS of 13.2 months versus 8.3 months, respectively (HR 0.78; 95% CI: 0.50-1.21).
The safety profile of ENHERTU in DESTINY-Breast06 was consistent with previous breast cancer clinical trials with no new safety concerns identified. The most common grade 3 or higher treatment related treatment emergent adverse events (TEAEs) occurring in 5% or more of patients treated with ENHERTU were neutropenia (20.7%), leukopenia (6.9%) and anemia (5.8%). Interstitial lung disease (ILD) or pneumonitis occurred in 11.3% of patients treated with ENHERTU. The majority of ILD or pneumonitis events were low grade (grade 1 [n=7; 1.6%] or grade 2 [n=36; 8.3%]). There were three grade 3 ILD events (0.7%), zero grade 4 events and three grade 5 events (0.7%) as determined by an independent adjudication committee.
"This Priority Review highlights the potential to expand the existing indication of ENHERTU in HER2 low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2 ultralow," said Ken Takeshita, MD, Global Head, R&amp;D, Daiichi Sankyo. "We look forward to working closely with the FDA with the goal of bringing ENHERTU to more patients as quickly as possible."
"While endocrine therapies are widely used in the initial treatment of HR positive metastatic breast cancer, most patients see limited benefit with additional lines of treatment and subsequent chemotherapy is associated with poor response rates and outcomes," said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology R&amp;D, AstraZeneca. "The results from DESTINY-Breast06 show that ENHERTU has the potential to evolve the current HR positive treatment landscape and become the first targeted treatment for patients with HER2 low or HER2 ultralow expression following endocrine therapy."

FDA Grants Priority Review for Daiichi Sankyo and AstraZeneca's ENHERTU in Breast Cancer Treatment

TransCode Therapeutics announces proposed common stock offering

TransCode Therapeutics stock slides after pricing stock offering to raise $3 million

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!



Moving stocks this morning are earnings reports, a settlement agreement, the pricing of a public offering and more.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is rocketing close to 254% alongside heavy pre-market trading.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are soaring more than 122% with strong early morning trading.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is surging nearly 78% with heavy early morning trading today.</li>



<li>Frequency Electronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/feim-stock-quote/">FEIM</a>) shares are rising almost 33% alongside its <a href="https://www.marketwatch.com/story/frequency-electronics-shares-climb-on-higher-4q-earnings-a32189da">Q4 earnings report</a>.</li>



<li>Mammoth Energy Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/tusk-stock-quote/">TUSK</a>) stock is heading over 29% higher after <a href="https://www.nasdaq.com/press-release/cobra-acquisitions-llc-announces-settlement-agreement-prepa-2024-07-22">announcing a settlement agreement</a>.</li>



<li>ENGlobal (NASDAQ:<a href="https://investorplace.com/stock-quotes/eng-stock-quote/">ENG</a>) shares are gaining more than 22% without any clear news.</li>



<li>Wheeler Real Estate IT (NASDAQ:<a href="https://investorplace.com/stock-quotes/whlr-stock-quote/">WHLR</a>) stock is jumping over 20% with no news to report.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are climbing more than 19% despite a lack of news on Tuesday.</li>



<li>SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) stock is getting an over 15% boost on a <a href="https://www.nasdaq.com/press-release/scynexis-receive-10-million-milestone-payment-gsk-triggered-delivery-completed-furi">$10 million milestone payment</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) shares are up more than 13% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is crashing more than 59% after <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">pricing a public offering</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are plummeting close to 31% <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">after a massive rally yesterday</a>.</li>



<li>Brera (NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/">BREA</a>) stock is diving nearly 25% with strong pre-market trading this morning.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are tumbling over 22% <a href="https://www.benzinga.com/news/24/07/39892411/caremax-shares-are-up-by-more-than-200-what-you-need-to-know">after a rally yesterday</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is taking a more than 19% beating after a recent rally.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are sliding over 19% <a href="https://investorplace.com/2024/07/why-is-castellum-ctm-stock-moving-today/">alongside volatility yesterday</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling almost 16% as shares <a href="https://investorplace.com/2024/07/why-is-exicure-xcur-stock-down-27-today/">continue to come off a recent rally</a>.</li>



<li>Quoin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/">QNRX</a>) shares are dropping more than 15% today.</li>



<li>Polaris (NYSE:<a href="https://investorplace.com/stock-quotes/pii-stock-quote/">PII</a>) stock is slipping over 15% after <a href="https://www.marketwatch.com/story/polaris-stock-tumbles-11-after-earnings-fall-far-short-of-consensus-and-company-cuts-full-year-outlook-c3299335">missing earnings estimates</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares close out our pre-market stock movers down more than 14%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares.



TransCode Therapeutics is <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">selling 10 million shares</a> of its common stock for 30 cents each. This has it expecting to raise gross proceeds of $30 million from the public offering of RNAZ stock.



TransCode Therapeutics says it will use the money from this offering mostly for product development activities. That includes more clinical trials of TTX-MC138. This is its lead product candidate for the treatment of metastatic tumors.



<h2>What This Means for RNAZ Stock</h2>



A public offering increases the total number of outstanding shares on the market. That&rsquo;s a blow to current investors in RNAZ as it reduces their stakes in the company. This is one reason why TransCode Therapeutics&rsquo; stock is falling today.



On top of that, the public offering price is a significant discount over its prior closing price of 79 cents. It makes sense that the price of RNAZ stock would drop with it offering news shares for just 30 cents each.



RNAZ stock is down 62.1% as of Tuesday morning. That comes with about 1.4 million shares traded, as compared to a daily average of around 1.3 million shares.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock, as well as the biggest pre-market stock movers this morning. All of this info is ready to go at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-warrantee-wrnt-stock-up-129-today/">Why Is Warrantee (WRNT) Stock Up 129% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is down on Tuesday as the clinical-stage pharmaceutical company&rsquo;s shares come off of a major rally on Monday.



Shares of MIRA stock closed out Monday&rsquo;s normal trading hours up 627.4%. That came alongside heavy trading with <a href="https://finance.yahoo.com/quote/MIRA/">more than 153 million shares traded</a>. For comparison, its daily average trading volume is about 3.2 million shares.



Mira Pharmaceuticals stock experienced this rally after releasing data from a <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">pre-clinical study of Ketamir-2</a>. This is the company&rsquo;s novel oral ketamine analog designed to treat neurological and neuropsychiatric disorders.



The big news here is that the results were positive. This has the company excited about the prospect of furthering the development of Ketamir-2 and submitting an investigational new drug (IND) application for it.



<h2>MIRA Stock Movement on Tuesday</h2>



Considering the massive rally MIRA shares underwent yesterday, it makes sense they would give up some of those gains in the days to follow. This has the stock dropping 27.4% as of Tuesday morning.



Today&rsquo;s dip comes with more than 5.5 million shares changing hands this morning. That&rsquo;s already above its daily average trading volume but is well below yesterday&rsquo;s heavy trading.



Investors who are seeking out even more of the most recent stock market stories today will want to keep reading!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes everything happening with shares of TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock, Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>)&nbsp;stock and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-sentinelone-s-stock-amid-cybersecurity-carnage/">Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-down-27-today/">Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

TransCode Therapeutics announces closing of public offering

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TransCode Therapeutics (RNAZ – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Celcuity (CELC)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) just reported results for the second quarter of 2024.<ul><li>TransCode Therapeutics reported earnings per share of -74 cents. This was below the analyst estimate for EPS of -58 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rnaz-stock-earnings-transcode-therapeutics-for-q2-of-2024/">RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024

TransCode Therapeutics secures $2M grant for lead candidate

TransCode Therapeutics (RNAZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...

Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment Efficacy

BREA

CELC

CMAX

FEIM

GNLN

IPDN

MIRA

NCPL

NMHI

NUKK

QNRX

RNAZ

SCYX

SOAR

TUSK

WHLR

WRNT

Press Releases

TransCode Therapeutics Open Letter to Shareholders

Health Care

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

Biotech

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Financing

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer

Comments

TransCode Therapeutics

Noticias

Últimas noticias sobre TransCode Therapeutics (NASDAQ:RNAZ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL